mRNA Synthesis & Manufacturing Market

Report Code BT 9194
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

mRNA Synthesis & Manufacturing Market by Product (Consumables [Transcription, Purification, Analysis & Characterization], Instrument), Service (Synthesis, Purification, Manufacturing & Scale-up), Application (CGT, Vaccines) - Global Forecast to 2029

Overview

The mRNA synthesis and manufacturing market is projected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024. This market is projected to grow at a CAGR of 3.4% over the forecast period. The primary drivers behind the expansion of this industry are the Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mRNA technology, advancements in mRNA synthesis technology, increased outsourcing for mRNA synthesis and modification, and collaborations among industry players. However, stability, storage, and manufacturing scalability present a challenge to this industry. This is further amplified by the slow patient adoption rate and the complexity of the development of mRNA-based therapy.

In many important respects, artificial intelligence (AI) is transforming the mRNA synthesis and manufacturing sector. First, by scanning large databases to find suitable mRNA sequences for therapeutic usage, artificial intelligence speeds up drug research and development greatly. Developed tools like the LinearDesign AI aim to maximize mRNA sequences, therefore producing vaccines with more antibody responses than conventional techniques. From raw material acquisition to final product packaging, artificial intelligence maximizes several manufacturing steps, thereby lowering costs and raising efficiency. AI-powered predictive maintenance reduces downtime and guarantees manufacturing equipment's seamless running.

Attractive Opportunities in the mRNA Synthesis & Manufacturing Market

Asia Pacific

The growth of the Asia Pacific mRNA synthesis and manufacturing market is primarily due to the emerging healthcare and biotechnology industries, government support, and funding potential for personalized medicines.

The growing demand for personalized medicines is significantly boosting the mRNA synthesis and manufacturing market.

Advancements in drug delivery technologies.

High production cost, Stability, storage, and manufacturing scalability.

The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period. The rising investments by governments and industries would drive growth.

Global mRNA Synthesis & Manufacturing Market Dynamics

DRIVER: Growing demand of personalized medicines

The growing demand for personalized medicines is significantly boosting the mRNA synthesis and manufacturing market. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, is leading to more effective and targeted therapies. For instance, in cancer treatment, personalized mRNA vaccines are being developed to target specific mutations in a patient’s tumor. Companies like BioNTech and Moderna are at the forefront, creating mRNA-based cancer vaccines that stimulate an immune response against the tumor. Similarly, mRNA therapies are being explored for rare genetic disorders, such as Translate Bio’s work on cystic fibrosis, aiming to correct the underlying genetic defect.

The success of mRNA vaccines for COVID-19 has also paved the way for personalized vaccines for other infectious diseases. This adaptability allows for quick responses to new virus strains, providing a personalized approach to vaccination. Investment in mRNA technology has surged, with companies like Moderna and BioNTech receiving billions in funding. For example, in July 2024, the US government has awarded USD 176.0 million to vaccine maker Moderna for development of an mRNA-based influenza shot. Additionally, there has been a significant increase in clinical trials involving mRNA therapies. As of 2023, over 150 clinical trials were registered for mRNA-based therapies, covering a wide range of diseases from cancer to infectious diseases.

RESTRAINT: High production cost

The high production costs of mRNA synthesis and manufacturing significantly restrain market growth due to several factors. The raw materials required, such as capping agents, nucleotides, and plasmid DNA, are expensive and often have a limited supply chain, driving up costs. The complex manufacturing process involves multiple steps, including transcription, purification, and formulation, each requiring specialized equipment and highly skilled personnel. Ensuring regulatory compliance adds another layer of cost, as rigorous testing for safety, efficacy, and quality demands significant investment. Additionally, establishing and maintaining the necessary infrastructure for mRNA production is capital-intensive, with advanced technologies like nanoparticle delivery systems needed to protect mRNA molecules and ensure their effective delivery. Supply chain disruptions can further impact production timelines and costs, as seen during the COVID-19 pandemic when the demand for mRNA vaccines surged.

For instance, according to the Covid-19 TechBrief process Cost Modelling, cost of production of mRNA-1273 vaccine is USD 2.7 per dose. Moreover, according to a BMJ report in January 2021, Moderna and Pfizer were charging more affluent nations and the EU for their mRNA vaccines with prices ranging from USD 14.70 to USD 23.50 a dose. Despite these challenges, the market for mRNA synthesis and manufacturing is expected to grow, driven by the increasing demand for mRNA-based vaccines and therapeutics. However, addressing these cost-related issues will be crucial for sustainable growth.

RESTRAINT: High production cost

The high production costs of mRNA synthesis and manufacturing significantly restrain market growth due to several factors. The raw materials required, such as capping agents, nucleotides, and plasmid DNA, are expensive and often have a limited supply chain, driving up costs. The complex manufacturing process involves multiple steps, including transcription, purification, and formulation, each requiring specialized equipment and highly skilled personnel. Ensuring regulatory compliance adds another layer of cost, as rigorous testing for safety, efficacy, and quality demands significant investment. Additionally, establishing and maintaining the necessary infrastructure for mRNA production is capital-intensive, with advanced technologies like nanoparticle delivery systems needed to protect mRNA molecules and ensure their effective delivery. Supply chain disruptions can further impact production timelines and costs, as seen during the COVID-19 pandemic when the demand for mRNA vaccines surged.

For instance, according to the Covid-19 TechBrief process Cost Modelling, cost of production of mRNA-1273 vaccine is USD 2.7 per dose. Moreover, according to a BMJ report in January 2021, Moderna and Pfizer were charging more affluent nations and the EU for their mRNA vaccines with prices ranging from USD 14.70 to USD 23.50 a dose. Despite these challenges, the market for mRNA synthesis and manufacturing is expected to grow, driven by the increasing demand for mRNA-based vaccines and therapeutics. However, addressing these cost-related issues will be crucial for sustainable growth.

 

 

OPPORTUNITY: Advancements in drug delivery technologies

Advancements in drug delivery technologies present a significant opportunity for the mRNA synthesis and manufacturing market by enhancing the efficacy and application range of mRNA-based therapies. Innovations in lipid nanoparticles (LNPs) have become crucial, as they efficiently encapsulate mRNA, protecting it from degradation and ensuring its effective cellular delivery, with ongoing improvements leading to better stability, reduced toxicity, and enhanced cellular uptake. Similarly, polymeric nanoparticles offer controlled release and targeted delivery of mRNA, which can improve therapeutic outcomes and broaden the scope of treatable conditions.

Additionally, advancements in targeted delivery systems, such as ligand-receptor interactions and antibody-based approaches, enable more precise delivery of mRNA to specific cell types or tissues, enhancing the therapeutic effectiveness and reducing side effects. Technologies for cell-specific delivery, including cell-penetrating peptides and aptamer-based systems, further allow for targeted treatment of diseases like cancer or genetic disorders, increasing the appeal of mRNA therapies. Moreover, the development of long-acting formulations that provide sustained release of mRNA reduces the need for frequent dosing, improving patient compliance and treatment outcomes. These advancements collectively drive the expansion of mRNA applications and create substantial growth opportunities in the mRNA synthesis and manufacturing market.

CHALLENGES: Stability, storage, and manufacturing scalability

The synthesis and manufacturing of mRNA face significant challenges, particularly in terms of stability, storage, and scalability. mRNA molecules are inherently unstable and prone to degradation by RNases, necessitating careful handling and protection throughout the manufacturing process. Chemical modifications, such as incorporating modified nucleosides, are often required to enhance stability and improve protein translation efficiency. Additionally, mRNA vaccines require ultra-cold storage conditions to maintain stability, posing logistical challenges, especially in regions with limited cold chain infrastructure.

The formulation of mRNA with lipid nanoparticles (LNPs) is crucial for stability, as LNPs protect the mRNA from degradation and facilitate its delivery into cells, but ensuring the long-term stability of these formulations remains a challenge. Scaling up mRNA production to meet global demand is also difficult, as traditional biopharmaceutical manufacturing facilities are often not equipped to handle the unique requirements of mRNA production. There is a lack of dedicated equipment and consumables specifically designed for mRNA processing, leading to inefficiencies and inconsistencies in the manufacturing process. Furthermore, ensuring consistent quality and meeting regulatory standards across large-scale production batches is complex, requiring meticulous control and validation of each step in the manufacturing process.

Global mRNA Synthesis & Manufacturing Market Ecosystem Analysis

The ecosystem analysis of the mRNA synthesis and manufacturing market offers a comprehensive view of the interconnected network of stakeholders, resources, and interactions that define the industry's dynamics. Central to this ecosystem are diverse entities engaged in manufacturing, distributing, and utilizing mRNA products and services. This includes raw materials providers, product providers, service providers, and end-users such as pharmaceutical & biotechnology companies, academic & research institutes, CROs and CMOs. Raw materials suppliers include those companies which provide ultracentrifuges, liquid handlers, fluorescence and absorbance readers, etc. which are essential components in mRNA synthesis and manufacturing. Regulatory authorities and standards bodies also play pivotal roles, influencing market trends, innovation, and the ethical use of genomic data. Understanding this complex network is crucial for navigating and driving advancements in mRNA technologies.

 

The transcription consumables segment accounted for the largest share by consumables product segment in the mRNA synthesis and manufacturing market in 2023

The mRNA synthesis and manufacturing consumables segment includes transcription consumables, purification consumables, and analysis & characterization consumables. The transcription consumables segment accounted for the largest share by consumables product segment in the mRNA synthesis and manufacturing market in 2023. The increasing focus on high-throughput mRNA production is a significant driver for the transcription consumables market, significantly boosting the demand for essential reagents and materials. The urgency for large-scale mRNA synthesis became especially pronounced during the COVID-19 pandemic, with Pfizer-BioNTech and Moderna rapidly scaling up their vaccine production. Pfizer-BioNTech’s vaccine and Moderna’s vaccine were granted Emergency Use Authorization by the FDA, both necessitating substantial quantities of transcription consumables to meet global demand. This shift led to the adoption of advanced automated systems to streamline production, such as Moderna recently announced another expansion of its manufacturing facility in Norwood, Massachusetts. This latest expansion, revealed on September 15, 2024, aims to further increase production capacity for mRNA vaccines and therapeutics. Also, in 2023, BioNTech announced significant advancements in its mRNA production technology, including the launch of a new high-throughput facility in Germany designed to support a range of mRNA applications, from vaccines to therapeutic products.

The vaccines segment accounted for the largest share by application segment in the mRNA synthesis and manufacturing market in 2023

Based on applications, the mRNA synthesis and manufacturing market is segmented into cell and gene therapy, vaccine and other applications. The vaccines segment accounted for the largest share by application segment in the mRNA synthesis and manufacturing market in 2023. A major driver for the mRNA synthesis and manufacturing market in the vaccine application is the accelerating development and deployment of mRNA vaccines for a variety of infectious diseases beyond COVID-19, which necessitates advanced, scalable manufacturing technologies. The remarkable success of mRNA COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, has not only proven the efficacy of mRNA technology but also catalysed interest in applying it to other infectious diseases. For example, in 2023, Moderna began advancing its mRNA vaccine pipeline with new candidates for diseases like influenza and respiratory syncytial virus (RSV), aiming to leverage mRNA technology to provide broader protection against seasonal and emerging pathogens. Similarly, in September 2024, Pfizer is to pay German company BioNTech up to USD 425.0 million for a multi-year collaboration in the development of more effective influenza vaccines, joining other pharma giants in a promising mRNA-based race. These initiatives highlight the growing need for sophisticated mRNA synthesis and manufacturing capabilities to meet the demands of large-scale vaccine production. Recent advancements include the expansion of mRNA production facilities by companies such as Lonza and Thermo Fisher Scientific, which have introduced new manufacturing technologies and optimized processes to support the increased production capacity required for these vaccines.

The pharmaceutical & biotechnology segment is expected to emerge as an attractive end user segment in the mRNA synthesis and manufacturing market in 2023

Based on service by end user, the mRNA synthesis and manufacturing services market is segmented into, pharmaceutical and biotechnology companies, academic and research institutions, and small-scale CROs & CDMOs. Pharmaceutical and biotechnology companies are poised to dominate the mRNA synthesis and manufacturing services market due to their significant resources, expertise, and established infrastructures, which enable rapid development and commercialization of mRNA-based products. As of 2023, the success of mRNA vaccines during the COVID-19 pandemic has not only validated the technology but has also prompted major players like Moderna and BioNTech to expand their capabilities and pipelines beyond vaccines. For example, in June 2023, Moderna announced plans to invest USD 1.0 billion in expanding its manufacturing facilities, aiming to enhance its production capacity for a broader range of mRNA therapeutics, including personalized cancer vaccines and treatments for rare diseases. This trend is mirrored by Pfizer, which has also increased investments in mRNA technology to develop therapeutics targeting various health conditions. Additionally, these companies are forming strategic collaborations with academic institutions and smaller biotech firms to leverage cutting-edge research and optimize manufacturing processes. As the demand for innovative therapies continues to grow, the combination of financial investment, technological advancement, and collaborative efforts positions pharmaceutical and biotechnology companies at the forefront of the mRNA synthesis and manufacturing services market, likely allowing them to capture a substantial share in the coming years.

The North American region accounted for the largest share of the mRNA synthesis and manufacturing market in 2023

The mRNA synthesis and manufacturing market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest market share in in 2023, while Europe became the second-largest market. One of the significant drivers for the US mRNA synthesis and manufacturing market is the increasing demand for mRNA-based vaccines and therapeutics, spurred by the success of COVID-19 mRNA vaccines. The rapid adoption of mRNA technology during the pandemic highlighted its potential, leading to substantial investments and advancements in this field. For instance, in June 2023, the US government announced a USD 1.7 billion investment to bolster domestic mRNA manufacturing capabilities, aimed at ensuring rapid responses to future pandemics and enhancing national health security. Additionally, the US Defence Advanced Research Projects Agency (DARPA) announced a USD 41.0 million grant to develop a manufacturing platform for new mRNA vaccines. These developments, coupled with the growing pipeline of mRNA-based products and the establishment of RNA research centers at institutions like the Yale Center for RNA Science and Medicine, are driving the market forward. The increasing awareness of the advantages of mRNA-based vaccines and the therapeutic applications of RNA technology further bolster this growth.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION

Recent Developments of mRNA Synthesis & Manufacturing Market

  • In May 2024, GenScript launched self-amplifying RNA synthesis service for advanced therapeutic applications. These enhances the potency and efficacy of vaccines, immunotherapies, and gene therapies.
  • In April 2024, New England Biolabs (US) company launched Monarch Mag Viral DNA/RNA Extraction Kit to enhance recovery of small amounts of viral nucleic acid.
  • In January 2024, Thermo Fisher Scientific Inc. received approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site.
  • In September 2023, Merck KGaA invested USD 29.0 million in 2 new mRNA production plants based in Germany.

Key Market Players

KEY PLAYERS IN THE MRNA SYNTHESIS AND MANUFACTURING MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in mRNA Synthesis & Manufacturing Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million)
Segments covered Product, Application, Service, and End Users
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

 

Key Questions Addressed by the Report

Who are the key players in the mRNA synthesis and manufacturing market?
Key players in the global mRNA synthesis and manufacturing market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), GenScript (US), New England Biolabs (US), AldevronLLC. (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (US), TriLink BioTechnologies (US), Lonza (Switzerland), Telesis Bio Inc. (US), and Aurigene Pharmaceutical Services Ltd. (India).
Which product dominates the mRNA synthesis and manufacturing market?
The consumables segment dominated the mRNA synthesis and manufacturing market in 2023.
Which application segment of the global mRNA synthesis and manufacturing market is expected to witness the highest growth?
The cell and gene therapy segment is expected to witness the highest growth in the forecast period. This is attributed to the increasing demand for personalized therapies and is supported by regulatory approvals and a large clinical pipeline.
What is the size of the mRNA synthesis and manufacturing market?
The mRNA synthesis and manufacturing market is estimated to account for USD 624.4 million in 2024.
What is the growth rate of the mRNA synthesis and manufacturing market?
The global mRNA synthesis and manufacturing market is expected to grow at 3.4% CAGR during the forecast period of 2024-2029.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the mRNA Synthesis & Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
34
RESEARCH METHODOLOGY
38
EXECUTIVE SUMMARY
51
PREMIUM INSIGHTS
55
MARKET OVERVIEW
57
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rise in clinical trials for mRNA vaccines
    - Continuous improvements in design, delivery systems, and manufacturing processes
    - Increased outsourcing of mRNA synthesis and production
    - Advantages of mRNA-based technology over recombinant expression
    RESTRAINTS
    - High production cost
    - Stringent regulations
    OPPORTUNITIES
    - Ongoing innovations in nanoparticles and cell-specific delivery technologies
    - Expanding applications of mRNA technology
    - Increased government funding and private investments
    CHALLENGES
    - Stability, storage, and manufacturing scalability issues
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 REGULATORY LANDSCAPE
    REGULATORY SCENARIO
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - In vitro transcription
    - Poly(A) tail synthesis
    - RNA stabilization technologies
    COMPLEMENTARY TECHNOLOGIES
    - Next-generation sequencing
    - Gene cloning and vector construction
    - DNA amplification
    ADJACENT TECHNOLOGIES
    - Spectrophotometry
    - Electrophoresis
    - High-performance liquid chromatography
  • 5.7 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT
    AVERAGE SELLING PRICE TREND, BY CONSUMABLES
    AVERAGE SELLING PRICE, BY REGION
  • 5.8 PATENT ANALYSIS
  • 5.9 SUPPLY CHAIN ANALYSIS
  • 5.10 ECOSYSTEM ANALYSIS
  • 5.11 KEY CONFERENCES AND EVENTS, 2024–2025
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA, BY PRODUCT END USER
  • 5.14 INVESTMENT AND FUNDING SCENARIO
  • 5.15 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET
MRNA SYNTHESIS AND MANUFACTURING MARKET, BY PRODUCT
89
  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    TRANSCRIPTION CONSUMABLES
    - mRNA synthesis kits
    - mRNA profiling kits
    - RNA polymerases
    - Plasmid DNA/DNA templates
    - Nucleotides
    - Vectors
    - Other transcription consumables
    PURIFICATION CONSUMABLES
    - Purification kits & reagents
    - Chromatography filters & membranes
    - Other purification consumables
    ANALYSIS & CHARACTERIZATION CONSUMABLES
    - Analysis kits & reagents
    - Other analysis & characterization consumables
  • 6.3 INSTRUMENTS
    NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH
MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION
128
  • 7.1 INTRODUCTION
  • 7.2 CELL & GENE THERAPIES
    RISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET
  • 7.3 VACCINES
    INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH
  • 7.4 OTHER APPLICATIONS
MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER
136
  • 8.1 INTRODUCTION
  • 8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET
  • 8.3 ACADEMIC & RESEARCH INSTITUTIONS
    INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH
  • 8.4 CROS & CDMOS
    RISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH
MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE
145
  • 9.1 INTRODUCTION
  • 9.2 MRNA SYNTHESIS & MODIFICATION
    GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET
  • 9.3 MRNA PURIFICATION
    NEED FOR PERSONALIZED MRNA VACCINES FOR CANCER AND RARE GENETIC DISORDERS TO BOOST MARKET
  • 9.4 MRNA ANALYSIS & CHARACTERIZATION
    INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH
  • 9.5 MANUFACTURING & SCALE-UP
    GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET
MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER
155
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH
  • 10.3 ACADEMIC & RESEARCH INSTITUTIONS
    INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH
  • 10.4 SMALL-SCALE CROS & CDMOS
    NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET
MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION
165
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth
    CANADA
    - Increasing collaborations between academic institutions and market players to spur growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Growing establishment of manufacturing sites to boost market
    UK
    - Presence of state-of-the art facilities to support growth
    FRANCE
    - Favorable government support for biopharmaceutical production to drive market
    SWITZERLAND
    - Robust biotech sector and production facilities to promote growth
    ITALY
    - Increasing collaborations among biotech firms and manufacturing facilities to aid growth
    SPAIN
    - Growing investments in biotechnology to boost market
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Rapid expansion of domestic biotech sector to contribute to growth
    JAPAN
    - Growing strategic investments in biotechnology infrastructure to support growth
    INDIA
    - Booming biotech sector and international collaborations to augment growth
    SOUTH KOREA
    - Increased government funding in research and vaccine development to bolster growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increased funding for strengthening infrastructure to sustain growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET
    MACROECONOMIC OUTLOOK IN MIDDLE EAST
  • 11.7 AFRICA
    GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
252
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.3 REVENUE ANALYSIS, 2019–2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
    MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET
    MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Product footprint
    - Service footprint
    - Application footprint
    - Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.8 BRAND/SERVICE COMPARISON
    ALDEVRON, LLC. (DANAHER CORPORATION) (US)
    THERMO FISHER SCIENTIFIC INC. (US)
    TRILINK BIOTECHNOLOGIES (US)
    LONZA (SWITZERLAND)
    MERCK KGAA (GERMANY)
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT/SERVICE LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
271
  • 13.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    LONZA
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    MARVAI LIFESCIENCES
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    NEW ENGLAND BIOLABS
    - Business overview
    - Products/services offered
    - Recent developments
    PROMEGA CORPORATION
    - Business overview
    - Products/services offered
    - Recent developments
    GENSCRIPT
    - Business overview
    - Products/services offered
    - Recent developments
    - MnM view
    WUXI BIOLOGICS
    - Business overview
    - Products/services offered
    - Recent developments
    TAKARA BIO INC.
    - Business overview
    - Products/services offered
    - Recent developments
    SARTORIUS AG
    - Business overview
    - Products/services offered
    - Recent developments
    GENEWIZ
    - Business overview
    - Products/services offered
    TELESIS BIO INC.
    - Business overview
    - Products/services offered
    - Recent developments
    ST PHARM
    - Business overview
    - Products/services offered
    - Recent developments
    AGC BIOLOGICS
    - Business overview
    - Products/services offered
    - Recent developments
    DR. REDDY’S LABORATORIES LTD.
    - Business overview
    - Products/services offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    ETHERNA
    BOC SCIENCES
    BIOMAY AG
    CURIA GLOBAL, INC.
    JENA BIOSCIENCE GMBH
    ENZYNOMICS CO., LTD.
    KANEKA EUROGENTEC S.A.
    VERNAL BIOSCIENCES
    CELLSCRIPT
APPENDIX
334
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 MRNA SYNTHESIS & MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 MRNA SYNTHESIS & MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 4 INDICATIVE LIST OF MRNA VACCINES IN CLINICAL TRIALS (AS OF JUNE 2023)
  • TABLE 5 INDICATIVE LIST OF MRNA-BASED DRUGS IN CLINICAL TRIALS (AS OF JUNE 2023)
  • TABLE 6 REGULATORY SCENARIO FOR MRNA SYNTHESIS & MANUFACTURING MARKET WORLDWIDE
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT, 2021–2023 (USD)
  • TABLE 12 AVERAGE SELLING PRICE TREND, BY CONSUMABLES, 2021–2023 (USD)
  • TABLE 13 AVERAGE SELLING PRICE, BY REGION, 2023 (USD)
  • TABLE 14 MRNA SYNTHESIS & MANUFACTURING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024
  • TABLE 15 MRNA SYNTHESIS & MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 16 MRNA SYNTHESIS & MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
  • TABLE 17 MRNA SYNTHESIS & MANUFACTURING MARKET: IMPACT OF PORTER’S FIVE FORCES
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
  • TABLE 19 KEY BUYING CRITERIA, BY PRODUCT END USER
  • TABLE 20 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 21 MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 22 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 EUROPE: MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 MRNA SYNTHESIS & MANUFACTURING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 TRANSCRIPTION CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 28 TRANSCRIPTION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 NORTH AMERICA: TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 EUROPE: TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 LATIN AMERICA: TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 MRNA SYNTHESIS KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 34 NORTH AMERICA: MRNA SYNTHESIS KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 EUROPE: MRNA SYNTHESIS KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: MRNA SYNTHESIS KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 LATIN AMERICA: MRNA SYNTHESIS KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 MRNA PROFILING KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 39 NORTH AMERICA: MRNA PROFILING KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 EUROPE: MRNA PROFILING KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: MRNA PROFILING KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 LATIN AMERICA: MRNA PROFILING KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 RNA POLYMERASES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 NORTH AMERICA: RNA POLYMERASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 EUROPE: RNA POLYMERASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: RNA POLYMERASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 LATIN AMERICA: RNA POLYMERASES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 PLASMID DNA/DNA TEMPLATES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: PLASMID DNA/DNA TEMPLATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 EUROPE: PLASMID DNA/DNA TEMPLATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: PLASMID DNA/DNA TEMPLATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: PLASMID DNA/DNA TEMPLATES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 NUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: NUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 EUROPE: NUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: NUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 LATIN AMERICA: NUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 VECTORS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 59 NORTH AMERICA: VECTORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 EUROPE: VECTORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: VECTORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 LATIN AMERICA: VECTORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 OTHER TRANSCRIPTION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: OTHER TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 EUROPE: OTHER TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: OTHER TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 LATIN AMERICA: OTHER TRANSCRIPTION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 PURIFICATION CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 69 PURIFICATION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 EUROPE: PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 LATIN AMERICA: PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 PURIFICATION KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: PURIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 EUROPE: PURIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: PURIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 LATIN AMERICA: PURIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 CHROMATOGRAPHY FILTERS & MEMBRANES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: CHROMATOGRAPHY FILTERS & MEMBRANES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: CHROMATOGRAPHY FILTERS & MEMBRANES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: CHROMATOGRAPHY FILTERS & MEMBRANES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: CHROMATOGRAPHY FILTERS & MEMBRANES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 OTHER PURIFICATION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: OTHER PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 EUROPE: OTHER PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: OTHER PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: OTHER PURIFICATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 90 ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 EUROPE: ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 LATIN AMERICA: ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 ANALYSIS KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 EUROPE: ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 LATIN AMERICA: ANALYSIS KITS & REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 OTHER ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 101 NORTH AMERICA: OTHER ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 EUROPE: OTHER ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: OTHER ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 LATIN AMERICA: OTHER ANALYSIS & CHARACTERIZATION CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 106 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 EUROPE: MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 111 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CELL & GENE THERAPIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 112 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 117 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 122 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 127 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 128 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 129 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 133 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 136 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 138 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 143 MRNA SYNTHESIS & MODIFICATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: MRNA SYNTHESIS & MODIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 EUROPE: MRNA SYNTHESIS & MODIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: MRNA SYNTHESIS & MODIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: MRNA SYNTHESIS & MODIFICATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 148 MRNA PURIFICATION SERVICES MARKET FOR, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 149 NORTH AMERICA: MRNA PURIFICATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 EUROPE: MRNA PURIFICATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: MRNA PURIFICATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 LATIN AMERICA: MRNA PURIFICATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 153 MRNA ANALYSIS & CHARACTERIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 154 NORTH AMERICA: MRNA ANALYSIS & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 EUROPE: MRNA ANALYSIS & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: MRNA ANALYSIS & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 LATIN AMERICA: MRNA ANALYSIS & CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 158 MANUFACTURING & SCALE-UP SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 159 NORTH AMERICA: MANUFACTURING & SCALE-UP SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 EUROPE: MANUFACTURING & SCALE-UP SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: MANUFACTURING & SCALE-UP SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 LATIN AMERICA: MANUFACTURING & SCALE-UP SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 164 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 170 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 171 EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 172 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 173 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR SMALL-SCALE CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR SMALL-SCALE CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 176 EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR SMALL-SCALE CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR SMALL-SCALE CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET FOR SMALL-SCALE CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 180 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 188 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 190 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 191 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 192 MACROECONOMIC INDICATORS FOR NORTH AMERICA
  • TABLE 193 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 194 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 195 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 196 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 197 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 198 US: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 199 US: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 200 US: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 201 US: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 202 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 203 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 204 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 205 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 206 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 207 CANADA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 208 CANADA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 209 CANADA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 210 CANADA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 211 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 212 EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 213 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 214 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 215 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 216 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 217 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 218 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 219 EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 220 EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 221 EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 222 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 223 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 224 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 225 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 226 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 227 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 228 GERMANY: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 229 GERMANY: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 230 GERMANY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 231 GERMANY: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 232 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 233 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 234 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 235 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 236 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 237 UK: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 238 UK: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 239 UK: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 240 UK: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 241 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 242 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 243 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 244 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 245 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 246 FRANCE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 247 FRANCE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 248 FRANCE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 249 FRANCE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 250 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 251 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 252 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 253 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 254 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 255 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 256 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 257 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 258 SWITZERLAND: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 259 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 260 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 261 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 262 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 263 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 264 ITALY: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 265 ITALY: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 266 ITALY: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 267 ITALY: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 268 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 269 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 270 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 271 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 272 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 273 SPAIN: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 274 SPAIN: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 275 SPAIN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 276 SPAIN: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 277 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 279 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 280 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 281 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 282 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 283 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 284 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 285 REST OF EUROPE: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 286 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 288 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 289 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 290 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 291 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 292 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 293 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 295 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 296 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 297 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 298 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 299 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 300 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 301 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 302 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 303 CHINA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 304 CHINA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 305 CHINA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 306 CHINA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 307 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 308 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 309 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 310 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 311 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 312 JAPAN: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 313 JAPAN: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 314 JAPAN: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 315 JAPAN: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 316 INDIA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 317 INDIA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 318 INDIA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 319 INDIA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 320 INDIA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 321 INDIA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 322 INDIA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 323 C: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 324 INDIA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 325 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 326 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 327 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 328 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 329 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 330 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 331 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 332 SOUTH KOREA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 333 SOUTH KOREA: MRNA SYNTHESIS AND MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 334 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 335 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 336 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 337 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 338 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 339 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 340 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 341 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 342 REST OF ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 343 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 344 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 345 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 346 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 347 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 348 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 349 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 350 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 351 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 352 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 353 LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 354 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 355 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 356 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 357 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 358 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 359 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 360 BRAZIL: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 361 BRAZIL: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 362 BRAZIL: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 363 BRAZIL: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 364 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 365 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 366 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 367 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 368 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 369 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 370 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 371 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 372 REST OF LATIN AMERICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 373 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 374 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 375 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 376 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 377 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 378 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 379 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 380 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 381 MIDDLE EAST: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 382 MACROECONOMIC INDICATORS FOR MIDDLE EAST
  • TABLE 383 AFRICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 384 AFRICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 385 AFRICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY TRANSCRIPTION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 386 AFRICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PURIFICATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 387 AFRICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY ANALYSIS & CHARACTERIZATION CONSUMABLES, 2022–2029 (USD MILLION)
  • TABLE 388 AFRICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 389 AFRICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 390 AFRICA: MRNA SYNTHESIS A&ND MANUFACTURING MARKET, BY SERVICE, 2022–2029 (USD MILLION)
  • TABLE 391 AFRICA: MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 392 MACROECONOMIC INDICATORS FOR AFRICA
  • TABLE 393 OVERVIEW OF STRATEGIES ADOPTED BY KEY MRNA SYNTHESIS & MANUFACTURING COMPANIES
  • TABLE 394 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET: DEGREE OF COMPETITION
  • TABLE 395 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET: DEGREE OF COMPETITION, 2023
  • TABLE 396 MRNA SYNTHESIS & MANUFACTURING MARKET: PRODUCT FOOTPRINT
  • TABLE 397 MRNA SYNTHESIS & MANUFACTURING MARKET: SERVICE FOOTPRINT
  • TABLE 398 MRNA SYNTHESIS & MANUFACTURING MARKET: APPLICATION FOOTPRINT
  • TABLE 399 MRNA SYNTHESIS & MANUFACTURING MARKET: REGION FOOTPRINT
  • TABLE 400 MRNA SYNTHESIS & MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 401 MRNA SYNTHESIS AND MANUFACTURING MARKET: COMPANY FOOTPRINT (STARTUPS/SMES)
  • TABLE 402 MRNA SYNTHESIS & MANUFACTURING MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 403 MRNA SYNTHESIS & MANUFACTURING MARKET: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 404 MRNA SYNTHESIS & MANUFACTURING MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 405 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 406 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 407 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 408 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 409 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 410 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 411 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 412 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 413 DANAHER CORPORATION: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 414 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 415 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 416 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 417 MERCK KGAA: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 418 MERCK KGAA: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 419 LONZA: COMPANY OVERVIEW
  • TABLE 420 LONZA: PRODUCTS/SERVICES OFFERED
  • TABLE 421 LONZA: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 422 LONZA: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 423 MARVAI LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 424 MARVAI LIFESCIENCES: PRODUCTS/SERVICES OFFERED
  • TABLE 425 MARVAI LIFESCIENCES: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 426 MARVAI LIFESCIENCE: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 427 TRILINK BIOTECHNOLOGIES (MARVAI LIFESCIENCES): EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 428 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 429 NEW ENGLAND BIOLABS: PRODUCTS/SERVICES OFFERED
  • TABLE 430 NEW ENGLAND BIOLABS: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 431 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 432 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 433 PROMEGA CORPORATION: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 434 PROMEGA CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024
  • TABLE 435 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 436 GENSCRIPT: PRODUCTS/SERVICES OFFERED
  • TABLE 437 GENSCRIPT: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 438 GENSCRIPT: DEALS, JANUARY 2021– AUGUST 2024
  • TABLE 439 GENSCRIPT: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 440 WUXI BIOLOGICS: COMPANY OVERVIEW
  • TABLE 441 WUXI BIOLOGICS: PRODUCTS/SERVICES OFFERED
  • TABLE 442 WUXI BIOLOGICS: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 443 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 444 TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 445 TAKARA BIO INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 446 TAKARA BIO INC.: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 447 SARTORIUS AG: COMPANY OVERVIEW
  • TABLE 448 SARTORIUS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 449 SARTORIUS AG: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 450 GENEWIZ: COMPANY OVERVIEW
  • TABLE 451 GENEWIZ: PRODUCTS/SERVICES OFFERED
  • TABLE 452 TELESIS BIO INC.: COMPANY OVERVIEW
  • TABLE 453 TELESIS BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 454 TELESIS BIO INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–AUGUST 2024
  • TABLE 455 TELESIS BIO INC.: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 456 ST PHARM: COMPANY OVERVIEW
  • TABLE 457 ST PHARM: PRODUCTS/SERVICES OFFERED
  • TABLE 458 ST PHARM: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 459 AGC BIOLOGICS: COMPANY OVERVIEW
  • TABLE 460 AGC BIOLOGICS: PRODUCTS/SERVICES OFFERED
  • TABLE 461 AGC BIOLOGICS: DEALS, JANUARY 2021–AUGUST 2024
  • TABLE 462 AGC BIOLOGICS: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 463 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
  • TABLE 464 DR. REDDY’S LABORATORIES LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 465 DR. REDDY’S LABORATORIES LTD.: EXPANSIONS, JANUARY 2021–AUGUST 2024
  • TABLE 466 ETHERNA: COMPANY OVERVIEW
  • TABLE 467 BOC SCIENCES: COMPANY OVERVIEW
  • TABLE 468 BIOMAY AG: COMPANY OVERVIEW
  • TABLE 469 CURIA GLOBAL, INC.: COMPANY OVERVIEW
  • TABLE 470 JENA BIOSCIENCE GMBH: COMPANY OVERVIEW
  • TABLE 471 ENZYNOMICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 472 KANEKA EUROGENTEC S.A.: COMPANY OVERVIEW
  • TABLE 473 VERNAL BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 474 CELLSCRIPT: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 MRNA SYNTHESIS & MANUFACTURING MARKET SEGMENTATION
  • FIGURE 2 MRNA SYNTHESIS & MANUFACTURING MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 4 MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) (PRODUCT), 2023
  • FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 2 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) (SERVICE), 2023
  • FIGURE 8 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2023
  • FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 10 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 11 MRNA SYNTHESIS & MANUFACTURING PRODUCTS MARKET: CAGR PROJECTIONS, 2024–2029
  • FIGURE 12 MRNA SYNTHESIS & MANUFACTURING SERVICES MARKET: CAGR PROJECTIONS, 2024–2029
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 20 EXPANDING APPLICATIONS OF MRNA TECHNOLOGY IS EXPECTED TO DRIVE THE GROWTH
  • FIGURE 21 CONSUMABLES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 MRNA SYNTHESIS & MODIFICATION TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 23 MRNA SYNTHESIS & MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN MRNA SYNTHESIS & MANUFACTURING MARKET
  • FIGURE 25 MRNA SYNTHESIS & MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 26 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT, 2021–2023 (USD)
  • FIGURE 27 AVERAGE SELLING PRICE TREND, BY CONSUMABLES, 2021–2023 (USD)
  • FIGURE 28 AVERAGE SELLING PRICE, BY REGION, 2023 (USD)
  • FIGURE 29 MRNA SYNTHESIS & MANUFACTURING MARKET: PATENT ANALYSIS, 2014–2024
  • FIGURE 30 MRNA SYNTHESIS & MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 31 MRNA SYNTHESIS & MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 32 MRNA SYNTHESIS & MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
  • FIGURE 34 KEY BUYING CRITERIA, BY PRODUCT END USER
  • FIGURE 35 RESEARCH FUNDING FOR MRNA SYNTHESIS & MANUFACTURING BY INSTITUTES AND CENTERS, 2021–2024 (USD MILLION)
  • FIGURE 36 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET
  • FIGURE 37 MRNA SYNTHESIS & MANUFACTURING INSTRUMENTS MARKET, BY VOLUME, 2022–2029
  • FIGURE 38 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: MRNA SYNTHESIS & MANUFACTURING MARKET SNAPSHOT
  • FIGURE 40 MRNA SYNTHESIS & MANUFACTURING MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2019–2023 (USD MILLION)
  • FIGURE 41 MRNA SYNTHESIS & MANUFACTURING MARKET SHARE ANALYSIS, 2023
  • FIGURE 42 MRNA SYNTHESIS & MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 43 MRNA SYNTHESIS & MANUFACTURING MARKET: COMPANY FOOTPRINT
  • FIGURE 44 MRNA SYNTHESIS & MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 45 EV/EBITDA OF KEY VENDORS
  • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 47 MRNA SYNTHESIS AND MANUFACTURING MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS
  • FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 51 LONZA: COMPANY SNAPSHOT (2023)
  • FIGURE 52 MARVAI LIFESCIENCES: COMPANY SNAPSHOT (2023)
  • FIGURE 53 GENSCRIPT: COMPANY SNAPSHOT (2023)
  • FIGURE 54 WUXI BIOLOGICS: COMPANY SNAPSHOT (2023)
  • FIGURE 55 TAKARA BIO INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 SARTORIUS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 57 GENEWIZ: COMPANY SNAPSHOT (2023)
  • FIGURE 58 TELESIS BIO INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 ST PHARM: COMPANY SNAPSHOT (2023)
  • FIGURE 60 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)

The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.

Secondary Research

The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the mRNA synthesis and manufacturing market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition

mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.

The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.

Stakeholders

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Raw Material Suppliers
  • Market Research and Consulting Firms
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Industry Associations and Professional Societies

Report Objectives

  • To define, describe, and forecast the mRNA synthesis and manufacturing market based on product, service, application, and region
  • To define, describe, and forecast the mRNA synthesis and manufacturing market based on product by end user and service by end user
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the mRNA synthesis and manufacturing market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global mRNA synthesis and manufacturing market and comprehensively analyze their products and services portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as product/service launches, expansions, agreements, and collaborations in the mRNA synthesis and manufacturing market
  • To benchmark players within the mRNA synthesis and manufacturing market using the Company Evaluation Matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in mRNA Synthesis & Manufacturing Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status